Global RNA Based Therapeutics Market By RNA Modality (Small interfering RNA (siRNA), Micro RNA (miRNA), Antisense Oligonucleotide (ASO), Others); By Route of Administration (Intravenous, Subcutaneous, Others); By Therapeutic Indication (Oncology, Cardiovascular Disease, Genetic Diseases, Infectious Diseases, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia(Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia) Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
The RNA based therapeutics market is witnessing significant growth owing to increasing prevalence of chronic diseases such as cancer, tuberculosis, and other genetic diseases. Worldwide, cancer is a leading cause of death and as per WHO, cancer accounted for nearly 10 million deaths in 2020. Breast cancer is one of the most lethal cancer and RNA therapy has emerged as a highly attractive class of drugs for the treatment and prevention of breast cancer. Also, cardiovascular disease is the biggest socio-economic burden and future threat to public health. Currently, several of RNA have enabled development of RNA-based therapeutics for a broad array of applications. Many emerging biopharmaceutical players are developing RNA interference (RNAi)-based, and RNA- based antisense oligonucleotide therapies. Additionally, the commercial availability of siRNAs to silence virtually any gene in the human genome is dramatically accelerating the pace of molecular diagnosis and biomedical research. Thus, increasing application of RNAi in molecular diagnosis is another factor leading for the demand of RNA based therapeutics market. Additionally, government approving the use mRNA based therapies for clinical use is adding fuel to the market growth. For instance, in 2018, U.S. FDA approved the first therapeutic RNA-based oligonucleotide.Moreover, the collaboration activities between the pharmaceutical companies and contract research organizations (CROs) working on drug delivery is expected to positively impact the market demand. The outbreak of covid 19 created an opportunity for the market to grow. Key players in the market are continuously focusing on the development of vaccines for coronavirus. Companies like Pfizer-BioNTech and Moderna developed a mRNA vaccine for COVID-19.
In terms of revenue, the global RNA based therapeutics market was valued at US$ 4721.82 in 2020 growing at a CAGR of 16.87% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global RNA Based Therapeutics Market Revenue & Forecast, (US$ Billion), 2015 – 2029
RNA Modality Outlook
By modality outlook, global RNA based therapeutics market has been segmented into small interfering RNA (siRNA), Micro RNA (miRNA), Antisense Oligonucleotide (ASO), and others. The antisense oligonucleotide registered for the largest market share in 2020 owing to the advantages offered by the antisense oligonucleotide therapy. This therapy produces a lasting clinical effect and is highly specific to the target and antisense oligonucleotides can be manufactured fairly fast. Moreover, they exhibit broader applications such as cancer therapy, treatment of antibiotic resistant bacterial infections, etc. Also, they hold a great potential for treating CNS disease. The approvals of ASO drugs is fueling for the RNA based therapeutics market growth. For instance, three ASO drugs have received FDA approval, nusinersen (Ionis Pharmaceuticals); eteplirsen (Sarepta Therapeutics); and inotersen (Ionis Pharmaceuticals and Akcea Therapeutics).
Route of Administration Outlook
Based on route of administration, the Global RNA Based Therapeutics Market is segmented into intravenous, subcutaneous, and others. Among these, the intravenous segment dominates the market as it maximizes the bioavailability of ASOs and lead to rapid distribution to organs like liver, kidney, spleen.
Therapeutic Indication Outlook
By therapeutic indication, the global RNA based therapeutics market is segmented into oncology, cardiovascular disease, genetic diseases, infectious diseases and others. The oncology segment dominates the market owing to increasing prevalence of cancer cases worldwide. Worldwide, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2021. This rising number of cancer patients have raised the demand for cancer therapies. Companies and institutes such as Enzon Pharmaceuticals,University of Texas, OncoGenex, Isarna Therapeutics, Astrazeneca are developing pipelines for cancer therapies. In addition, many companies have invested in R&D for nanocarriers to deliver oligonucleotides for cancer treatment, which is expected to contribute to the segment growth.
Region Outlook
The RNA based therapeutics market is divided into four regions: North America, Asia-Pacific, Europe, Latin America and Middle East & Africa. In 2020, North America dominated the market, accounting for the largest share, and this trend is expected to continue throughout the forecast period. Research efforts for RNA-based treatments are expected to increase in North America as a result of strong infrastructure for developmental research, the availability of substantial research funds, and increased government initiatives toward RNA-based therapeutics.
Competitive Landscape
The report provides both, qualitative and quantitative research of the global RNA based therapeutics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysis in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the key players operating in the global RNA based therapeutics market are:
- Alnylam Pharmaceuticals, Inc.
- Arbutus Biopharma
- Arrowhead Pharmaceuticals, Inc.
- Benitec Biopharma
- Dicerna Pharmaceuticals, Inc.
- Ionis Pharmaceuticals
- Sarepta Therapeutics
- Secarna Pharmaceuticals GmbH & Co. KG
- Silence Therapeutics
- Skyhawk Therapeutics, Inc.
- Viridian Therapeutics, Inc.
- Other Market Participants
Global RNA Based Therapeutics Market
By RNA Modality
- Small interfering RNA (siRNA)
- Micro RNA (miRNA)
- Antisense Oligonucleotide (ASO)
- Others
By Route of Administration
- Intravenous
- Subcutaneous
- Others
By Therapeutic Indication
- Oncology
- Cardiovascular Disease
- Genetic Diseases
- Infectious Diseases
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of RNA Based Therapeutics Market
6.
Market
Synopsis: RNA Based Therapeutics Market
7.
RNA
Based Therapeutics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in RNA Based Therapeutics Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
RNA Based Therapeutics Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on RNA Based Therapeutics
Market
8.
Global
RNA Based Therapeutics Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global RNA Based Therapeutics Market Revenue
(US$ Mn)
8.2. Global RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
8.2.1. Small interfering RNA (siRNA)
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market
Forecast, 2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5.
Latin America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Micro RNA (miRNA)
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Antisense Oligonucleotide (ASO)
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.3.3.
Market
Forecast, 2021 - 2029
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.2.4. Others
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.4.3.
Market
Forecast, 2021 - 2029
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2020
8.2.4.5.1.2. Market Forecast, 2021 - 2029
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2020
8.2.4.5.2.2. Market Forecast, 2021 - 2029
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2020
8.2.4.5.3.2. Market Forecast, 2021 - 2029
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2020
8.2.4.5.4.2. Market Forecast, 2021 - 2029
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2020
8.2.4.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By RNA Modality
9.
Global
RNA Based Therapeutics Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
9.2.1. Intravenous
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2. Subcutaneous
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3. Others
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.3.3.
Market
Forecast, 2021 - 2029
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Route of Administration
10. Global RNA Based Therapeutics Market
Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
10.2.1. Oncology
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Cardiovascular Disease
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.2.3. Genetic Diseases
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2020
10.2.3.5.1.2. Market Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2020
10.2.3.5.2.2. Market Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2020
10.2.3.5.3.2. Market Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2020
10.2.3.5.4.2. Market Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2020
10.2.3.5.5.2. Market Forecast, 2021 - 2029
10.2.4. Infectious Diseases
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 -
2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 - 2020
10.2.4.5.1.2. Market Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2020
10.2.4.5.2.2. Market Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2020
10.2.4.5.3.2. Market Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2020
10.2.4.5.4.2. Market Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 - 2020
10.2.4.5.5.2. Market Forecast, 2021 - 2029
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2020
10.2.5.3. Market Forecast, 2021 - 2029
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 - 2020
10.2.5.5.1.2. Market Forecast, 2021 - 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2020
10.2.5.5.2.2. Market Forecast, 2021 - 2029
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2020
10.2.5.5.3.2. Market Forecast, 2021 - 2029
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2020
10.2.5.5.4.2. Market Forecast, 2021 - 2029
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 - 2020
10.2.5.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Therapeutic Indication
11. North America RNA Based Therapeutics Market
Analysis and Forecasts, 2021 - 2029
11.1. Overview
11.1.1. North America RNA Based Therapeutics Market
Revenue (US$ Mn)
11.2. North America RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
11.2.1. Small interfering RNA (siRNA)
11.2.2. Micro RNA (miRNA)
11.2.3. Antisense Oligonucleotide (ASO)
11.2.4. Others
11.3. North America RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
11.3.1. Intravenous
11.3.2. Subcutaneous
11.3.3. Others
11.4. North America RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.4.1. Oncology
11.4.2. Cardiovascular Disease
11.4.3. Genetic Diseases
11.4.4. Infectious Diseases
11.4.5. Others
11.5. North America RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
11.5.1.1.1. Small interfering RNA (siRNA)
11.5.1.1.2. Micro RNA (miRNA)
11.5.1.1.3. Antisense Oligonucleotide (ASO)
11.5.1.1.4. Others
11.5.1.2. U.S RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
11.5.1.2.1. Intravenous
11.5.1.2.2. Subcutaneous
11.5.1.2.3. Others
11.5.1.3. U.S RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
11.5.1.3.1. Oncology
11.5.1.3.2. Cardiovascular Disease
11.5.1.3.3. Genetic Diseases
11.5.1.3.4. Infectious Diseases
11.5.1.3.5. Others
11.5.2. Canada
11.5.2.1. Canada RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
11.5.2.1.1. Small interfering RNA (siRNA)
11.5.2.1.2. Micro RNA (miRNA)
11.5.2.1.3. Antisense Oligonucleotide (ASO)
11.5.2.1.4. Others
11.5.2.2. Canada RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
11.5.2.2.1. Intravenous
11.5.2.2.2. Subcutaneous
11.5.2.2.3. Others
11.5.2.3. Canada RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
11.5.2.3.1. Oncology
11.5.2.3.2. Cardiovascular Disease
11.5.2.3.3. Genetic Diseases
11.5.2.3.4. Infectious Diseases
11.5.2.3.5. Others
11.5.3. Mexico
11.5.3.1. Mexico RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
11.5.3.1.1. Small interfering RNA (siRNA)
11.5.3.1.2. Micro RNA (miRNA)
11.5.3.1.3. Antisense Oligonucleotide (ASO)
11.5.3.1.4. Others
11.5.3.2. Mexico RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
11.5.3.2.1. Intravenous
11.5.3.2.2. Subcutaneous
11.5.3.2.3. Others
11.5.3.3. Mexico RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
11.5.3.3.1. Oncology
11.5.3.3.2. Cardiovascular Disease
11.5.3.3.3. Genetic Diseases
11.5.3.3.4. Infectious Diseases
11.5.3.3.5. Others
11.5.4. Rest of North America
11.5.4.1. Rest of North America RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By RNA Modality
11.5.4.1.1. Small interfering RNA (siRNA)
11.5.4.1.2. Micro RNA (miRNA)
11.5.4.1.3. Antisense Oligonucleotide (ASO)
11.5.4.1.4. Others
11.5.4.2. Rest of North America RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
11.5.4.2.1. Intravenous
11.5.4.2.2. Subcutaneous
11.5.4.2.3. Others
11.5.4.3. Rest of North America RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.5.4.3.1. Oncology
11.5.4.3.2. Cardiovascular Disease
11.5.4.3.3. Genetic Diseases
11.5.4.3.4. Infectious Diseases
11.5.4.3.5. Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By RNA Modality
11.6.3. By Route of Administration
11.6.4. By Therapeutic Indication
12. Europe RNA Based Therapeutics Market
Analysis and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. Europe RNA Based Therapeutics Market Revenue
(US$ Mn)
12.2. Europe RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
12.2.1. Small interfering RNA (siRNA)
12.2.2. Micro RNA (miRNA)
12.2.3. Antisense Oligonucleotide (ASO)
12.2.4. Others
12.3. Europe RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.3.1. Intravenous
12.3.2. Subcutaneous
12.3.3. Others
12.4. Europe RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
12.4.1. Oncology
12.4.2. Cardiovascular Disease
12.4.3. Genetic Diseases
12.4.4. Infectious Diseases
12.4.5. Others
12.5. Europe RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
12.5.1.1.1. Small interfering RNA (siRNA)
12.5.1.1.2. Micro RNA (miRNA)
12.5.1.1.3. Antisense Oligonucleotide (ASO)
12.5.1.1.4. Others
12.5.1.2. France RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.5.1.2.1. Intravenous
12.5.1.2.2. Subcutaneous
12.5.1.2.3. Others
12.5.1.3. France RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
12.5.1.3.1. Oncology
12.5.1.3.2. Cardiovascular Disease
12.5.1.3.3. Genetic Diseases
12.5.1.3.4. Infectious Diseases
12.5.1.3.5. Others
12.5.2. The UK
12.5.2.1. The UK RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
12.5.2.1.1. Small interfering RNA (siRNA)
12.5.2.1.2. Micro RNA (miRNA)
12.5.2.1.3. Antisense Oligonucleotide (ASO)
12.5.2.1.4. Others
12.5.2.2. The UK RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.5.2.2.1. Intravenous
12.5.2.2.2. Subcutaneous
12.5.2.2.3. Others
12.5.2.3. The UK RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
12.5.2.3.1. Oncology
12.5.2.3.2. Cardiovascular Disease
12.5.2.3.3. Genetic Diseases
12.5.2.3.4. Infectious Diseases
12.5.2.3.5. Others
12.5.3. Spain
12.5.3.1. Spain RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
12.5.3.1.1. Small interfering RNA (siRNA)
12.5.3.1.2. Micro RNA (miRNA)
12.5.3.1.3. Antisense Oligonucleotide (ASO)
12.5.3.1.4. Others
12.5.3.2. Spain RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.5.3.2.1. Intravenous
12.5.3.2.2. Subcutaneous
12.5.3.2.3. Others
12.5.3.3. Spain RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
12.5.3.3.1. Oncology
12.5.3.3.2. Cardiovascular Disease
12.5.3.3.3. Genetic Diseases
12.5.3.3.4. Infectious Diseases
12.5.3.3.5. Others
12.5.4. Germany
12.5.4.1. Germany RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
12.5.4.1.1. Small interfering RNA (siRNA)
12.5.4.1.2. Micro RNA (miRNA)
12.5.4.1.3. Antisense Oligonucleotide (ASO)
12.5.4.1.4. Others
12.5.4.2. Germany RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.5.4.2.1. Intravenous
12.5.4.2.2. Subcutaneous
12.5.4.2.3. Others
12.5.4.3. Germany RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
12.5.4.3.1. Oncology
12.5.4.3.2. Cardiovascular Disease
12.5.4.3.3. Genetic Diseases
12.5.4.3.4. Infectious Diseases
12.5.4.3.5. Others
12.5.5. Italy
12.5.5.1. Italy RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
12.5.5.1.1. Small interfering RNA (siRNA)
12.5.5.1.2. Micro RNA (miRNA)
12.5.5.1.3. Antisense Oligonucleotide (ASO)
12.5.5.1.4. Others
12.5.5.2. Italy RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.5.5.2.1. Intravenous
12.5.5.2.2. Subcutaneous
12.5.5.2.3. Others
12.5.5.3. Italy RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
12.5.5.3.1. Oncology
12.5.5.3.2. Cardiovascular Disease
12.5.5.3.3. Genetic Diseases
12.5.5.3.4. Infectious Diseases
12.5.5.3.5. Others
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By RNA Modality
12.5.6.1.1. Small interfering RNA (siRNA)
12.5.6.1.2. Micro RNA (miRNA)
12.5.6.1.3. Antisense Oligonucleotide (ASO)
12.5.6.1.4. Others
12.5.6.2. Nordic Countries RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.5.6.2.1. Intravenous
12.5.6.2.2. Subcutaneous
12.5.6.2.3. Others
12.5.6.3. Nordic Countries RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.6.3.1. Oncology
12.5.6.3.2. Cardiovascular Disease
12.5.6.3.3. Genetic Diseases
12.5.6.3.4. Infectious Diseases
12.5.6.3.5. Others
12.5.6.4. Nordic Countries RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
12.5.7.1.1. Small interfering RNA (siRNA)
12.5.7.1.2. Micro RNA (miRNA)
12.5.7.1.3. Antisense Oligonucleotide (ASO)
12.5.7.1.4. Others
12.5.7.2. Benelux Union RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.5.7.2.1. Intravenous
12.5.7.2.2. Subcutaneous
12.5.7.2.3. Others
12.5.7.3. Benelux Union RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.7.3.1. Oncology
12.5.7.3.2. Cardiovascular Disease
12.5.7.3.3. Genetic Diseases
12.5.7.3.4. Infectious Diseases
12.5.7.3.5. Others
12.5.7.4. Benelux Union RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
12.5.8.1.1. Small interfering RNA (siRNA)
12.5.8.1.2. Micro RNA (miRNA)
12.5.8.1.3. Antisense Oligonucleotide (ASO)
12.5.8.1.4. Others
12.5.8.2. Rest of Europe RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
12.5.8.2.1. Intravenous
12.5.8.2.2. Subcutaneous
12.5.8.2.3. Others
12.5.8.3. Rest of Europe RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.8.3.1. Oncology
12.5.8.3.2. Cardiovascular Disease
12.5.8.3.3. Genetic Diseases
12.5.8.3.4. Infectious Diseases
12.5.8.3.5. Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By RNA Modality
12.6.3. By Route of Administration
12.6.4. By Therapeutic Indication
13. Asia Pacific RNA Based Therapeutics Market
Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Asia Pacific RNA Based Therapeutics Market
Revenue (US$ Mn)
13.2. Asia Pacific RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
13.2.1. Small interfering RNA (siRNA)
13.2.2. Micro RNA (miRNA)
13.2.3. Antisense Oligonucleotide (ASO)
13.2.4. Others
13.3. Asia Pacific RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.3.1. Intravenous
13.3.2. Subcutaneous
13.3.3. Others
13.4. Asia Pacific RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.4.1. Oncology
13.4.2. Cardiovascular Disease
13.4.3. Genetic Diseases
13.4.4. Infectious Diseases
13.4.5. Others
13.5. Asia Pacific RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
13.5.1.1.1. Small interfering RNA (siRNA)
13.5.1.1.2. Micro RNA (miRNA)
13.5.1.1.3. Antisense Oligonucleotide (ASO)
13.5.1.1.4. Others
13.5.1.2. China RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.5.1.2.1. Intravenous
13.5.1.2.2. Subcutaneous
13.5.1.2.3. Others
13.5.1.3. China RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
13.5.1.3.1. Oncology
13.5.1.3.2. Cardiovascular Disease
13.5.1.3.3. Genetic Diseases
13.5.1.3.4. Infectious Diseases
13.5.1.3.5. Others
13.5.2. Japan
13.5.2.1. Japan RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
13.5.2.1.1. Small interfering RNA (siRNA)
13.5.2.1.2. Micro RNA (miRNA)
13.5.2.1.3. Antisense Oligonucleotide (ASO)
13.5.2.1.4. Others
13.5.2.2. Japan RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.5.2.2.1. Intravenous
13.5.2.2.2. Subcutaneous
13.5.2.2.3. Others
13.5.2.3. Japan RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
13.5.2.3.1. Oncology
13.5.2.3.2. Cardiovascular Disease
13.5.2.3.3. Genetic Diseases
13.5.2.3.4. Infectious Diseases
13.5.2.3.5. Others
13.5.3. India
13.5.3.1. India RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
13.5.3.1.1. Small interfering RNA (siRNA)
13.5.3.1.2. Micro RNA (miRNA)
13.5.3.1.3. Antisense Oligonucleotide (ASO)
13.5.3.1.4. Others
13.5.3.2. India RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.5.3.2.1. Intravenous
13.5.3.2.2. Subcutaneous
13.5.3.2.3. Others
13.5.3.3. India RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
13.5.3.3.1. Oncology
13.5.3.3.2. Cardiovascular Disease
13.5.3.3.3. Genetic Diseases
13.5.3.3.4. Infectious Diseases
13.5.3.3.5. Others
13.5.4. New Zealand
13.5.4.1. New Zealand RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
13.5.4.1.1. Small interfering RNA (siRNA)
13.5.4.1.2. Micro RNA (miRNA)
13.5.4.1.3. Antisense Oligonucleotide (ASO)
13.5.4.1.4. Others
13.5.4.2. New Zealand RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.5.4.2.1. Intravenous
13.5.4.2.2. Subcutaneous
13.5.4.2.3. Others
13.5.4.3. New Zealand RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.4.3.1. Oncology
13.5.4.3.2. Cardiovascular Disease
13.5.4.3.3. Genetic Diseases
13.5.4.3.4. Infectious Diseases
13.5.4.3.5. Others
13.5.5. Australia
13.5.5.1. Australia RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
13.5.5.1.1. Small interfering RNA (siRNA)
13.5.5.1.2. Micro RNA (miRNA)
13.5.5.1.3. Antisense Oligonucleotide (ASO)
13.5.5.1.4. Others
13.5.5.2. Australia RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.5.5.2.1. Intravenous
13.5.5.2.2. Subcutaneous
13.5.5.2.3. Others
13.5.5.3. Australia RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
13.5.5.3.1. Oncology
13.5.5.3.2. Cardiovascular Disease
13.5.5.3.3. Genetic Diseases
13.5.5.3.4. Infectious Diseases
13.5.5.3.5. Others
13.5.6. South Korea
13.5.6.1. South Korea RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
13.5.6.1.1. Small interfering RNA (siRNA)
13.5.6.1.2. Micro RNA (miRNA)
13.5.6.1.3. Antisense Oligonucleotide (ASO)
13.5.6.1.4. Others
13.5.6.2. South Korea RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.5.6.2.1. Intravenous
13.5.6.2.2. Subcutaneous
13.5.6.2.3. Others
13.5.6.3. South Korea RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.6.3.1. Oncology
13.5.6.3.2. Cardiovascular Disease
13.5.6.3.3. Genetic Diseases
13.5.6.3.4. Infectious Diseases
13.5.6.3.5. Others
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
13.5.7.1.1. Small interfering RNA (siRNA)
13.5.7.1.2. Micro RNA (miRNA)
13.5.7.1.3. Antisense Oligonucleotide (ASO)
13.5.7.1.4. Others
13.5.7.2. Southeast Asia RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.5.7.2.1. Intravenous
13.5.7.2.2. Subcutaneous
13.5.7.2.3. Others
13.5.7.3. Southeast Asia RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.7.3.1. Oncology
13.5.7.3.2. Cardiovascular Disease
13.5.7.3.3. Genetic Diseases
13.5.7.3.4. Infectious Diseases
13.5.7.3.5. Others
13.5.7.4. Southeast Asia RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By RNA Modality
13.5.8.1.1. Small interfering RNA (siRNA)
13.5.8.1.2. Micro RNA (miRNA)
13.5.8.1.3. Antisense Oligonucleotide (ASO)
13.5.8.1.4. Others
13.5.8.2. Rest of Asia Pacific RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.5.8.2.1. Intravenous
13.5.8.2.2. Subcutaneous
13.5.8.2.3. Others
13.5.8.3. Rest of Asia Pacific RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.8.3.1. Oncology
13.5.8.3.2. Cardiovascular Disease
13.5.8.3.3. Genetic Diseases
13.5.8.3.4. Infectious Diseases
13.5.8.3.5. Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By RNA Modality
13.6.3. By Route of Administration
13.6.4. By Therapeutic Indication
14. Middle East and Africa RNA Based
Therapeutics Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Middle East and Africa RNA Based Therapeutics
Market Revenue (US$ Mn)
14.2. Middle East and Africa RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By RNA Modality
14.2.1. Small interfering RNA (siRNA)
14.2.2. Micro RNA (miRNA)
14.2.3. Antisense Oligonucleotide (ASO)
14.2.4. Others
14.3. Middle East and Africa RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.3.1. Intravenous
14.3.2. Subcutaneous
14.3.3. Others
14.4. Middle East and Africa RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.4.1. Oncology
14.4.2. Cardiovascular Disease
14.4.3. Genetic Diseases
14.4.4. Infectious Diseases
14.4.5. Others
14.5. Middle East and Africa RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
14.5.1.1.1. Small interfering RNA (siRNA)
14.5.1.1.2. Micro RNA (miRNA)
14.5.1.1.3. Antisense Oligonucleotide (ASO)
14.5.1.1.4. Others
14.5.1.2. Saudi Arabia RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.5.1.2.1. Intravenous
14.5.1.2.2. Subcutaneous
14.5.1.2.3. Others
14.5.1.3. Saudi Arabia RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.1.3.1. Oncology
14.5.1.3.2. Cardiovascular Disease
14.5.1.3.3. Genetic Diseases
14.5.1.3.4. Infectious Diseases
14.5.1.3.5. Others
14.5.2. UAE
14.5.2.1. UAE RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
14.5.2.1.1. Small interfering RNA (siRNA)
14.5.2.1.2. Micro RNA (miRNA)
14.5.2.1.3. Antisense Oligonucleotide (ASO)
14.5.2.1.4. Others
14.5.2.2. UAE RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.5.2.2.1. Intravenous
14.5.2.2.2. Subcutaneous
14.5.2.2.3. Others
14.5.2.3. UAE RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
14.5.2.3.1. Oncology
14.5.2.3.2. Cardiovascular Disease
14.5.2.3.3. Genetic Diseases
14.5.2.3.4. Infectious Diseases
14.5.2.3.5. Others
14.5.3. Egypt
14.5.3.1. Egypt RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
14.5.3.1.1. Small interfering RNA (siRNA)
14.5.3.1.2. Micro RNA (miRNA)
14.5.3.1.3. Antisense Oligonucleotide (ASO)
14.5.3.1.4. Others
14.5.3.2. Egypt RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.5.3.2.1. Intravenous
14.5.3.2.2. Subcutaneous
14.5.3.2.3. Others
14.5.3.3. Egypt RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
14.5.3.3.1. Oncology
14.5.3.3.2. Cardiovascular Disease
14.5.3.3.3. Genetic Diseases
14.5.3.3.4. Infectious Diseases
14.5.3.3.5. Others
14.5.4. Kuwait
14.5.4.1. Kuwait RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
14.5.4.1.1. Small interfering RNA (siRNA)
14.5.4.1.2. Micro RNA (miRNA)
14.5.4.1.3. Antisense Oligonucleotide (ASO)
14.5.4.1.4. Others
14.5.4.2. Kuwait RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.5.4.2.1. Intravenous
14.5.4.2.2. Subcutaneous
14.5.4.2.3. Others
14.5.4.3. Kuwait RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
14.5.4.3.1. Oncology
14.5.4.3.2. Cardiovascular Disease
14.5.4.3.3. Genetic Diseases
14.5.4.3.4. Infectious Diseases
14.5.4.3.5. Others
14.5.5. South Africa
14.5.5.1. South Africa RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
14.5.5.1.1. Small interfering RNA (siRNA)
14.5.5.1.2. Micro RNA (miRNA)
14.5.5.1.3. Antisense Oligonucleotide (ASO)
14.5.5.1.4. Others
14.5.5.2. South Africa RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.5.5.2.1. Intravenous
14.5.5.2.2. Subcutaneous
14.5.5.2.3. Others
14.5.5.3. South Africa RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.5.3.1. Oncology
14.5.5.3.2. Cardiovascular Disease
14.5.5.3.3. Genetic Diseases
14.5.5.3.4. Infectious Diseases
14.5.5.3.5. Others
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa RNA Based
Therapeutics Market Revenue (US$ Mn) and Forecasts, By RNA Modality
14.5.6.1.1. Small interfering RNA (siRNA)
14.5.6.1.2. Micro RNA (miRNA)
14.5.6.1.3. Antisense Oligonucleotide (ASO)
14.5.6.1.4. Others
14.5.6.2. Rest of Middle East & Africa RNA Based
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.5.6.2.1. Intravenous
14.5.6.2.2. Subcutaneous
14.5.6.2.3. Others
14.5.6.3. Rest of Middle East & Africa RNA Based
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.6.3.1. Oncology
14.5.6.3.2. Cardiovascular Disease
14.5.6.3.3. Genetic Diseases
14.5.6.3.4. Infectious Diseases
14.5.6.3.5. Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By RNA Modality
14.6.3. By Route of Administration
14.6.4. By Therapeutic Indication
15. Latin America RNA Based Therapeutics Market
Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Latin America RNA Based Therapeutics Market
Revenue (US$ Mn)
15.2. Latin America RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
15.2.1. Small interfering RNA (siRNA)
15.2.2. Micro RNA (miRNA)
15.2.3. Antisense Oligonucleotide (ASO)
15.2.4. Others
15.3. Latin America RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.3.1. Intravenous
15.3.2. Subcutaneous
15.3.3. Others
15.4. Latin America RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.4.1. Oncology
15.4.2. Cardiovascular Disease
15.4.3. Genetic Diseases
15.4.4. Infectious Diseases
15.4.5. Others
15.5. Latin America RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By RNA Modality
15.5.1.1.1. Small interfering RNA (siRNA)
15.5.1.1.2. Micro RNA (miRNA)
15.5.1.1.3. Antisense Oligonucleotide (ASO)
15.5.1.1.4. Others
15.5.1.2. Brazil RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.5.1.2.1. Intravenous
15.5.1.2.2. Subcutaneous
15.5.1.2.3. Others
15.5.1.3. Brazil RNA Based Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
15.5.1.3.1. Oncology
15.5.1.3.2. Cardiovascular Disease
15.5.1.3.3. Genetic Diseases
15.5.1.3.4. Infectious Diseases
15.5.1.3.5. Others
15.5.2. Argentina
15.5.2.1. Argentina RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By RNA Modality
15.5.2.1.1. Small interfering RNA (siRNA)
15.5.2.1.2. Micro RNA (miRNA)
15.5.2.1.3. Antisense Oligonucleotide (ASO)
15.5.2.1.4. Others
15.5.2.2. Argentina RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.5.2.2.1. Intravenous
15.5.2.2.2. Subcutaneous
15.5.2.2.3. Others
15.5.2.3. Argentina RNA Based Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.5.2.3.1. Oncology
15.5.2.3.2. Cardiovascular Disease
15.5.2.3.3. Genetic Diseases
15.5.2.3.4. Infectious Diseases
15.5.2.3.5. Others
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By RNA Modality
15.5.3.1.1. Small interfering RNA (siRNA)
15.5.3.1.2. Micro RNA (miRNA)
15.5.3.1.3. Antisense Oligonucleotide (ASO)
15.5.3.1.4. Others
15.5.3.2. Rest of Latin America RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.5.3.2.1. Intravenous
15.5.3.2.2. Subcutaneous
15.5.3.2.3. Others
15.5.3.3. Rest of Latin America RNA Based Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.5.3.3.1. Oncology
15.5.3.3.2. Cardiovascular Disease
15.5.3.3.3. Genetic Diseases
15.5.3.3.4. Infectious Diseases
15.5.3.3.5. Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By RNA Modality
15.6.3. By Route of Administration
15.6.4. By Therapeutic Indication
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2020
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. Alnylam Pharmaceuticals, Inc.
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Arbutus Biopharma
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. Arrowhead Pharmaceuticals, Inc.
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. Benitec Biopharma
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Dicerna Pharmaceuticals, Inc.
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Ionis Pharmaceuticals
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Sarepta Therapeutics
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. Secarna Pharmaceuticals GmbH & Co. KG
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. Silence Therapeutics
17.9.1. Company Details
17.9.2. Company Overview
17.9.3. Product Offerings
17.9.4. Key Developments
17.9.5. Financial Analysis
17.9.6. SWOT Analysis
17.9.7. Business Strategies
17.10. Skyhawk Therapeutics, Inc.
17.10.1. Company Details
17.10.2. Company Overview
17.10.3. Product Offerings
17.10.4. Key Developments
17.10.5. Financial Analysis
17.10.6. SWOT Analysis
17.10.7. Business Strategies
17.11. Viridian Therapeutics, Inc.
17.11.1. Company Details
17.11.2. Company Overview
17.11.3. Product Offerings
17.11.4. Key Developments
17.11.5. Financial Analysis
17.11.6. SWOT Analysis
17.11.7. Business Strategies
17.12. Other Market Participants
18. Key Findings
**Exclusive
for Multi-User and Enterprise User.
Note: This
ToC is tentative and can be changed according to the research study conducted
during the course of report completion.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.